| [1] |
TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800. |
| [2] |
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021. |
| [3] |
SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4. |
| [4] |
Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. |
| [5] |
LIANG XE, SUN J. Assessing the relationship between ALT level with disease progression and treatment timing[J]. Chin J Hepatol, 2020, 28(12): 992-994. DOI: 10.3760/cma.j.cn501113- 20201022-00571.
|
| [6] |
|
| [7] |
LESMANA CR, GANI RA, HASAN I, et al. Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia[J]. J Dig Dis, 2011, 12(6): 476-480. DOI: 10.1111/j.1751-2980.2011.00540.x. |
| [8] |
PARK JY, PARK YN, KIM DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels[J]. J Viral Hepat, 2008, 15(8): 615-621. DOI: 10.1111/j.1365-2893.2008.00989.x. |
| [9] |
GÖBEL T, ERHARDT A, HERWIG M, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe[J]. J Med Virol, 2011, 83(6): 968-973. DOI: 10.1002/jmv.22048. |
| [10] |
MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998. e4. DOI: 10.1053/j.gastro.2016.07.012. |
| [11] |
KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904. |
| [12] |
ZHU S, ZHANG H, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037. |
| [13] |
PODDAR U, YACHHA SK, AGARWAL J, et al. Cure for immune-tolerant hepatitis B in children: Is it an achievable target with sequential combo therapy with lamivudine and interferon?[J]. J Viral Hepat, 2013, 20(5): 311-316. DOI: 10.1111/jvh.12007. |
| [14] |
KIM HL, KIM GA, PARK JA, et al. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B[J]. Gut, 2020. DOI: 10.1136/gutjnl-2020-321309.[Online ahead of print] |
| [15] |
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6. |
| [16] |
Bureau of Disease Prevention and Control, Ministry of Health, Chinese Center for Disease Control and Prevention. Investigation Report on Serological Epidemiology of the Hepatitis B Virus Among the National Population in China[M]. Beijing: People's Medical Publishing House, 2011: 29.
卫生部疾病预防控制局, 中国疾病预防控制中心. 全国人群乙型病毒性肝炎血清流行病学调查报告[M]. 北京: 人民卫生出版社, 2011: 29.
|
| [17] |
JENG WJ, LOK AS. Should treatment indications for chronic hepatitis B be expanded?[J]. Clin Gastroenterol Hepatol, 2020. DOI: 10.1016/j.cgh.2020.04.091.[Online ahead of print] |
DownLoad: